Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Medical Innovation

Opinion: Former Merck CEO and Princeton University President Emeritus on ‘Trump’s War on Science Threatens U.S. Prosperity’

Princeton, NJ, June 12, 2017Roy Vagelos, retired Chairman and CEO of Merck & Co. and Chairman of the Board of Regeneron Pharmaceuticals, and Shirley Tilghman, President Emeritus of Princeton University and a professor of Molecular Biology and Public Affairs, published the following opinion piece in The Star-Ledger on June 6:

In the past 40 years, the U.S. has been the world leader in converting fundamental scientific discoveries into innovative new treatments for life-threatening disease.  New drugs, vaccines, and medical devices have improved human health and increased our lifespan. Continue reading

BioNJ’s BioPartnering Conference Delivered a Day of Innovation, Partnering and Learning

Trenton, NJ, June 10, 2017BioNJ’s Seventh Annual BioPartnering Conference, in partnership with J.P. Morgan, took place on May 23 at the Busch Campus Center, Rutgers University in Piscataway.

The event brought together 300 regional biopharma executives, investors, academic liaisons and business development professionals from the region for a day of education, networking and collaboration.

“We couldn’t be happier with the outcome of last week’s event,” said BioNJ President and CEO Debbie Hart. Continue reading

Three PhRMA Reports Highlight Increasing Global Competition in Biopharmaceutical R&D, Posing Challenges to Future U.S. Standing

Washington, DC, June 9, 2017 — As the U.S. looks to maintain its global leadership in biopharmaceutical research and development, three new reports point to an increasingly competitive global environment — one that requires a thorough assessment of our current public policies.

That includes the biopharmaceutical industry’s investments in science, technology, engineering and mathematics (STEM)-based initiatives at the state and national levels given the growing efforts of other countries to compete for the high-wage jobs and robust economic contributions of innovative biopharmaceutical companies.

“The American biopharmaceutical industry is the global leader in research and development (R&D) and has delivered many of the treatments and cures that have saved millions of lives around the world,” said Dr. Anne Pritchett, vice president, policy and research, at the Pharmaceutical Research and Manufacturers of America (PhRMA).  Continue reading

FDA Commissioner Gottlieb Ends Trump’s Hiring Freeze at Agency

Washington, DC, June 7, 2017 — Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., has pulled the plug on the hiring freeze President Donald Trump imposed on the agency.

The moves will allow the FDA to fill vacancies to shape an agency capable of enacting his plans for how safety and efficacy information are gathered during development. Continue reading

Trump Budget Proposes Deep Cuts to Medical Research and Health Care

Washington, DC, May 24, 2017 — Alison Kodjak and Rob Stein report on NPR that President Donald J. Trump’s proposed budget unveiled Tuesday doubles down on major cuts to biomedical research, programs to fight infectious disease outbreaks, health care for the poor, elderly and disabled, and prevention of HIV/AIDS.

The 2018 budget, which is entitled “A New Foundation for American Greatness,” restates the goals of the “skinny budget” the administration released in March, which was widely condemned by scientists and public health advocates. Continue reading

Trump Administration’s Hiring Freeze Means Nearly 700 Vacancies at CDC

Washington, DC, May 22, 2017 — Lena H. Sun reports in The Washington Post that nearly 700 positions are vacant at the Centers for Disease Control and Prevention (CDC) because of a continuing freeze on hiring that officials and researchers say affects programs supporting local and state public health emergency readiness, infectious disease control and chronic disease prevention.

The same restriction remains in place throughout the Health and Human Services Department (HHS) despite the lifting of a government-wide hiring freeze last month. Continue reading

Medical Innovation: COTA, IBM Watson Teaming Up for Pilot Program at Hackensack Meridian

New Brunswick, NJ, May 18, 2017 — Anjalee Khemlani reports on NJBIZ:

Imagine waiting for your diagnosis.

The doctor walks in and says, “Well, I just consulted with everyone on the planet Earth over the last 30 years to see how they took care of people like you, and then I looked at a database that precisely looked at people who have exactly what you have, and are exactly like you, and this is what I have learned in the past five minutes, and this is why I am going to recommend this treatment.”

That, said Dr. Andrew Pecora, is what the new pilot program between COTA and IBM Watson is all about. Continue reading

Biopharmaceutical Companies Unveil Latest GoBOLDLY TV Ad Showcasing ‘New World’ of Medicine

Washington, DC, May 17, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on May 15 unveiled its latest advertisement as part of its groundbreaking GOBOLDLY™ campaign, titled “New World, “featuring some of the most extraordinary breakthroughs in science being discovered by biopharmaceutical researchers.

“Biopharmaceutical researchers are driving unimaginable innovation in science, which is revolutionizing how the most complex diseases are treated,” said Stephen J. Ubl, president and chief executive officer of PhRMA.

“We truly are in a new world of medicine and on the verge of something even greater and more impactful. This promises a future with endless potential of scientific advances.” Continue reading

With an Emphasis on R&D, PhRMA Board of Directors Establishes New Membership Criteria

Washington, DC, May 11, 2017 — Demonstrating its commitment to representing research- based biopharmaceutical companies, the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA) on May 9 approved new criteria for membership.

Biopharmaceutical companies will now have to meet new research and development (R&D) requirements in order to be eligible to join PhRMA.

In making the announcement, Joaquin Duato, PhRMA board chairman and worldwide chairman, pharmaceuticals, Johnson & Johnson, said, “By putting in place new membership criteria, the board is sending a clear message that being a member of PhRMA means being committed to doing the time-intensive, scientifically sound research it takes to bring bold new advances in treatments and cures to patients.” Continue reading

Rutgers Research: Traumatic Brain Injuries May be Helped with Drug Used to Treat Bipolar Disorder

New Brunswick, NJ, May 10, 2017 — A drug used to treat bipolar disorder and other forms of depression may help to preserve brain function and prevent nerve cells from dying in people with a traumatic brain injury, according to a new Rutgers University study.

In research published in Scientific Reports on May 8, Rutgers scientists discovered that lithium — used as a mood stabilizer and to treat depression and bipolar disorder — and rapamycin, a treatment for some forms of cancer, protected nerve cells in the brain and stopped the chemical glutamate from sending signals to other cells and creating further brain cell damage. Continue reading